Urogen's Novel Formula For Urothelial Cancer Presents Unique Commercial Challenges
Executive Summary
The company expects to launch a proprietary gel formulation of chemo drug mitomycin for urothelial cancer in the first half of 2020.
You may also be interested in...
UroGen Wins First FDA Approval With Jelmyto For Urothelial Cancer
Jelmyto relies on a proprietary sustained-release drug delivery technology that UroGen plans to use for future drugs. The company is moving ahead with a launch in June, relying on virtual technology.
Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
UroGen's Lead Product Data Back Barrett's Interest
UroGen's reverse thermal gel formulation of mitomycin produced a high rate of complete responses in patients with urothelial cancer; developing a commercialization strategy for the product will benefit from the experience of the company's new CEO.